Can anti-IgE be used to treat allergy?

  title={Can anti-IgE be used to treat allergy?},
  author={Frances M. Davis and Lani A. Gossett and Kristi Pinkston and Ruey S. Liou and L. K. Sun and Y. W. Kim and Nancy T. Chang and T. W. Chang and Kathrin Wagner and J P Bews and Volker Brinkmann and Harry Towbin and Natarajan Subramanian and Christoph H. Heusser},
  journal={Springer Seminars in Immunopathology},
Summary and conclusionA summary of the properties of CGP 51901 is shown in Table 3. On the basis of its binding to IgE and IgE-secreting cells and its activity in vitro and in vivo, CGP 51901 is expected to be able to decrease serum IgE by direct clearance of IgE and by reduction of the numbers and productivity of IgE-secreting cells. The end result of reduction of IgE in the circulation and on mast cells is expected to be the attenuation of IgE-mediated reactions and the improvement in allergy… 

Anti-IgE as a mast cell-stabilizing therapeutic agent.

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

A pharmacokinetic-pharmacodynamic model incorporating omalizumab-IgE binding and feedback for control of IgE production indicates that omalIZumab reduces production of IgN, raising the possibility that indefinite treatment may not be required, only for perhaps a few years.

Will Anti-IgE Therapy Compromise Normal

The IgE-mediated immune mechanism seems to have a modest role in the protection of human subjects against the infection of parasitic worms since the defense function is handled by several redundant immune mechanisms.

Development and characterization of a novel anti-IgE monoclonal antibody.

B cells and food allergy

B cells play several roles in the development of food allergy versus tolerance and can be employed in other atopic diseases to better understand their pathogenesis and create new avenues for treatment.

Inhibition of human airway sensitization by a novel monoclonal anti-IgE antibody, 17-9.

It is concluded that allergen responses in sensitized human airways are dependent on IgE levels in the sensitizing serum while nonspecific (hyper)responsiveness depends on serum factors other than IgE.

Molecular aspects of allergy.

Past, present, and future of anti‐IgE biologics

The molecular properties of past and present anti‐IgE biologicals are highlighted and concepts that might improve treatment efficacy of future drug candidates are suggested.



IL-4 requirements for the generation of secondary in vivo IgE responses.

Evidence is provided that IL-4 is required for virgin B lymphocytes to develop into IgE-expressing cells, but is not required for B cells that express intrinsic membrane IgE to differentiate into Ig E-secreting cells in a T-dependent response.

Inhibition of IgE synthesis by anti-IgE: role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE.

  • S. HabaA. Nisonoff
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1990
Inoculation of syngeneic IgE into 2- to 12-day-old mice results in prolonged synthesis of anti-IgE antibodies without further challenge. These anti-IgE antibodies may be largely responsible for the

Anti-human IgG causes basophil histamine release by acting on IgG-IgE complexes bound to IgE receptors.

The ability of anti-human IgG antibodies to induce histamine release from human basophils is reexamined and it is concluded that anti-IgG-induced release occurs as a result of binding to IgG anti-iGE antibodies and cross-linking of the IgE receptors on basophil.

Human IgE-binding factors.

IgE-binding factors and regulation of the IgE antibody response.

  • K. Ishizaka
  • Biology, Medicine
    Annual review of immunology
  • 1988
If the same procedures would be effective for human T cells of allergic patients, it would be possible to generate antigen-specific suppressor T cells from their T cell population in vitro and to establish T cell hybridomas that produce allergen-specific GIF(TsF).

New concepts of IgE regulation.

It is demonstrated that in certain established immune situations the IgE response may become independent of IL-4, namely in the spontaneous in vitro IgE expression of cells from atopic individuals as well as in an in vitro antigen-induced secondary IgEresponse of spleen cells derived from previously immunized mice.

Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1.

Results indicate an important physiologic role for BSF-1 in the generation of IgE antibody responses and suggest means for limiting the production of antibodies responsible for allergic reactions without inhibiting protective antibody responses.

Induction of an auto‐anti‐IgE response in rats. I. Effects on serum IgE concentrations

With a view to specifically suppressing the IgE isotype, rats of high (BN) and low (PVG. RT1u) IgE‐responding phenotypes were immunized with a highly purified rat IgE myeloma (IR2) in an attempt to

A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma.

The addition of concanavalin A-stimulated supernatants of the helper T cell clone, D9.1, to cultures of lipopolysaccharide (LPS)-stimulated T-depleted mouse spleen cells caused more than a 100-fold

Monoclonal Antibodies Specific for Human IgE-Producing B Cells: A Potential Therapeutic for IgE-Mediated Allergic Diseases

Evidence is reported for the existence of antigenic epitopes on IgE that are accessible on Ig E-secreting B cells but not on other cells bearing IgE.